Activation of the Tubulo-Glomerular Feedback by SGLT2 Inhibitors in Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease: Toward the End of a Myth?

被引：11
|
作者：
Gerard, Alexandre O. [1 ,2 ]
Laurain, Audrey [1 ]
Favre, Guillaume [1 ]
Drici, Milou-Daniel [2 ]
Esnault, Vincent L. M. [1 ]
机构：
[1] Univ Cote Azur, Pasteur Hosp, Nephrol Dialysis Transplantat Dept, Nice, France
[2] Univ Cote Azur, Pasteur Hosp, Dept Pharmacol, Nice, France
来源：
DIABETES CARE | 2022年 / 45卷 / 10期
关键词：
D O I：
10.2337/dc22-0921
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：E148 / E149
页数：2
相关论文
共 50 条
  • [1] The effects of the SGLT2 inhibitors on the Japanese type 2 diabetes patients with chronic kidney disease
    Kobayashi, K.
    Sato, K.
    Hatori, N.
    Miyakawa, M.
    Toyoda, M.
    DIABETOLOGIA, 2017, 60 : S418 - S418
  • [2] The Kidney Effects of the SGLT2 Inhibitors on the Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease
    Kobayashi, Kazuo
    Toyoda, Masao
    Hatori, Nobuo
    Sakai, Hiroyuki
    Furuki, Takayuki
    Tamura, Kouichi
    Miyakawa, Masaaki
    DIABETES, 2019, 68
  • [3] SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
    David C. Wheeler
    June James
    Dipesh Patel
    Adie Viljoen
    Amar Ali
    Marc Evans
    Kevin Fernando
    Debbie Hicks
    Nicola Milne
    Philip Newland-Jones
    John Wilding
    Diabetes Therapy, 2020, 11 : 2757 - 2774
  • [4] SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
    Wheeler, David C.
    James, June
    Patel, Dipesh
    Viljoen, Adie
    Ali, Amar
    Evans, Marc
    Fernando, Kevin
    Hicks, Debbie
    Milne, Nicola
    Newland-Jones, Philip
    Wilding, John
    DIABETES THERAPY, 2020, 11 (12) : 2757 - 2774
  • [5] Understanding the protective effects of SGLT2 inhibitors in type 2 diabetes patients with chronic kidney disease
    Scheen, Andre J.
    Delanaye, Pierre
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2022, 17 (01) : 35 - 46
  • [6] Efficacy and safety profile of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
    Scheen, Andre J.
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (03) : 243 - 256
  • [7] Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease
    Kelly, Michael S.
    Lewis, Jelena
    Huntsberry, Ashley M.
    Dea, Lauren
    Portillo, Ivan
    POSTGRADUATE MEDICINE, 2019, 131 (01) : 31 - 42
  • [8] SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
    Kanduri, Swetha R.
    Kovvuru, Karthik
    Hansrivijit, Panupong
    Thongprayoon, Charat
    Vallabhajosyula, Saraschandra
    Pivovarova, Aleksandra I.
    Chewcharat, Api
    Garla, Vishnu
    Medaura, Juan
    Cheungpasitporn, Wisit
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09)
  • [9] SGLT2 Inhibitors for the Prevention of Kidney Failure in Patients with Type 2 Diabetes
    Pavlicek, Vojtech
    DIABETOLOGE, 2019, 15 (07): : 663 - 664
  • [10] Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
    Scheen, Andre J.
    CLINICAL PHARMACOKINETICS, 2015, 54 (07) : 691 - 708
12345